Evidence map›Paper›PMID 36100603›Full record

ArticleNPJ genomic medicine2022

Machine learning-based detection of immune-mediated diseases from genome-wide cell-free DNA sequencing datasets.

Huiwen Che, Tatjana Jatsenko, Lore Lannoo, Kate Stanley, Luc Dehaspe, Leen Vancoillie, Nathalie Brison, Ilse Parijs, Kris Van Den Bogaert, Koenraad Devriendt and 6 more

Open access · goldAbstract read
In one paragraph

Article in NPJ genomic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Huiwen CheDepartment of Human Genetics, Laboratory for Cytogenetics and Genome Research, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-3651-069X
Tatjana JatsenkoDepartment of Human Genetics, Laboratory for Cytogenetics and Genome Research, KU Leuven, Leuven, Belgium.
Lore LannooDepartment of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-6271-221X
Kate StanleyDepartment of Human Genetics, Laboratory for Cytogenetics and Genome Research, KU Leuven, Leuven, Belgium.
Luc DehaspeCentre for Human Genetics, University Hospitals Leuven, Leuven, Belgium.
Leen VancoillieCentre for Human Genetics, University Hospitals Leuven, Leuven, Belgium.
Nathalie BrisonCentre for Human Genetics, University Hospitals Leuven, Leuven, Belgium.
Ilse ParijsCentre for Human Genetics, University Hospitals Leuven, Leuven, Belgium.
Kris Van Den BogaertCentre for Human Genetics, University Hospitals Leuven, Leuven, Belgium.
Koenraad DevriendtCentre for Human Genetics, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-3651-2548
Sabien SeveriDepartment of Rheumatology, University Hospitals Leuven, Leuven, Belgium.
Ellen De LangheDepartment of Rheumatology, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-4045-2146
Severine VermeireDepartment of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-9942-3019
Bram VerstocktDepartment of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0003-3898-7093
Kristel Van CalsterenDepartment of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium.
Joris Robert VermeeschDepartment of Human Genetics, Laboratory for Cytogenetics and Genome Research, KU Leuven, Leuven, Belgium. joris.vermeesch@uzleuven.be.
KU Leuven · BECenter for Human Genetics · US

Funding

Agentschap Innoveren en Ondernemen (Flanders Innovation & Entrepreneurship) HBC.2018.2018Katholieke Universiteit Leuven | Universitaire Ziekenhuizen Leuven, KU Leuven (University Hospital Leuven, KU Leuven) RT 1065
6 · The paper itself

Abstract

The early detection of tissue and organ damage associated with autoimmune diseases (AID) has been identified as key to improve long-term survival, but non-invasive biomarkers are lacking. Elevated cell-free DNA (cfDNA) levels have been observed in AID and inflammatory bowel disease (IBD), prompting interest to use cfDNA as a potential non-invasive diagnostic and prognostic biomarker. Despite these known disease-related changes in concentration, it remains impossible to identify AID and IBD patients through cfDNA analysis alone. By using unsupervised clustering on large sets of shallow whole-genome sequencing (sWGS) cfDNA data, we uncover AID- and IBD-specific genome-wide patterns in plasma cfDNA in both the obstetric and general AID and IBD populations. We demonstrate that pregnant women with AID and IBD have higher odds of receiving inconclusive non-invasive prenatal screening (NIPS) results. Supervised learning of the genome-wide patterns allows AID prediction with 50% sensitivity at 95% specificity. Importantly, the method has the potential to identify pregnant women with AID during routine NIPS. Since AID pregnancies have an increased risk of severe complications, early recognition or detection of new-onset AID can redirect pregnancy management and limit potential adverse events. This method opens up new avenues for screening, diagnosis and monitoring of AID and IBD.

Identifiers

PMID36100603
PMCPMC9470560
OpenAlexW4295759980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.